(VIANEWS) – GUERBET (GBT.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Medical Devices industry.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| GUERBET (GBT.PA) | €32.85 | 1.42% | 8.14% |
| IBA (IBAB.BR) | €14.26 | 1.26% | 8.86% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. GUERBET (GBT.PA)
1.42% Forward Dividend Yield and 8.14% Return On Equity
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.
Earnings Per Share
As for profitability, GUERBET has a trailing twelve months EPS of €-3.35.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.14%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.9%, now sitting on 840.79M for the twelve trailing months.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 1, 2024, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 1.42%.
Volume
Today’s last reported volume for GUERBET is 14593 which is 41.9% below its average volume of 25120.
Moving Average
GUERBET’s value is under its 50-day moving average of €34.75 and above its 200-day moving average of €32.44.
More news about GUERBET.
2. IBA (IBAB.BR)
1.26% Forward Dividend Yield and 8.86% Return On Equity
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €0.27.
PE Ratio
IBA has a trailing twelve months price to earnings ratio of 52.81. Meaning, the purchaser of the share is investing €52.81 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.86%.
Volume
Today’s last reported volume for IBA is 122025 which is 504.77% above its average volume of 20177.
Moving Average
IBA’s worth is way higher than its 50-day moving average of €12.30 and way above its 200-day moving average of €12.25.
More news about IBA.
